

INFINITY PHARMACEUTICALS, INC.

Form 8-K

December 09, 2008

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 4, 2008

Infinity Pharmaceuticals, Inc.

(Exact name of registrant as specified in charter)

Delaware
(State or other jurisdiction
of incorporation)

000-31141
(Commission File Number)

33-0655706
(IRS Employer
Identification No.)

Edgar Filing: INFINITY PHARMACEUTICALS, INC. - Form 8-K

780 Memorial Drive, Cambridge, MA
(Address of principal executive offices)

02139
(Zip Code)

Registrant's telephone number, including area code: (617) 453-1000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) On December 4, 2008, our Board of Directors determined the annual contingent cash compensation awards for each of our named executive officers as follows:

	2008 Contingent Cash Compensation Award
Steven H. Holtzman	
Chief Executive Officer	\$ 288,000
Adelene Q. Perkins	
President and Chief Business Officer	
(principal financial officer)	\$ 195,000
Julian Adams	
President of Research & Development and Chief Scientific Officer	\$ 195,000

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

INFINITY PHARMACEUTICALS, INC.

Date: December 9, 2008

By: /s/ Gerald E. Quirk
Gerald E. Quirk
Vice President & General Counsel